AstraZeneca PLC (LON:AZN)
12,532
+36 (0.29%)
Oct 24, 2025, 5:43 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.71
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
194.33B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
AstraZeneca News
- 1 day ago - AstraZeneca found in breach of industry code over Symbicort marketing, industry body says - Reuters
- 3 days ago - Peering Into AstraZeneca PLC's Recent Short Interest - Benzinga
- 3 days ago - Novavax (NVAX) Sells Facility to AstraZeneca for $60M in Strategic Deal - GuruFocus
- 3 days ago - AstraZeneca's Tezspire Receives EU Approval for Severe Rhinosinusitis - GuruFocus
- 3 days ago - Novavax to assign Gaithersburg, Md. facility to AstraZeneca for $60B - Seeking Alpha
- 3 days ago - AstraZeneca Bolsters Oncology with £1.2 Billion Fusion Buyout Amid UK Growth - ABC Money
- 3 days ago - AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps - Nasdaq
- 3 days ago - AstraZeneca PLC (AZN) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha